Mabpharm Limited (HK:2181) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mabpharm Limited has received approval from the Indonesian National Agency of Drug and Food Control for their core product, CMAB008 (infliximab for injection), to treat several conditions including ulcerative colitis and rheumatoid arthritis. This biosimilar medicine, originating from China, offers a more economical option for patients due to its inclusion in China’s basic medical insurance program. Investors may find this approval promising as it expands Mabpharm’s market reach and potential revenue streams.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.